Pregnancy losses in women with type 1 or type 2 diabetes in the UK:an investigation using primary care records by McGrogan, A. et al.
        
Citation for published version:
McGrogan, A, Snowball, J & De Vries, CS 2014, 'Pregnancy losses in women with type 1 or type 2 diabetes in
the UK: an investigation using primary care records', Diabetic Medicine, vol. 31, no. 3, pp. 357-365.
https://doi.org/10.1111/dme.12332
DOI:
10.1111/dme.12332
Publication date:
2014
Document Version
Peer reviewed version
Link to publication
Full version of paper available from publisher's website at
http://onlinelibrary.wiley.com/doi/10.1111/dme.12332/abstract
University of Bath
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 13. May. 2019
1 
 
Pregnancy losses in women with type 1 or type 2 diabetes in the UK: an 
investigation using primary care records  
 
Anita McGrogan1, Julia Snowball1, Corinne S. de Vries1 
1 Department of Pharmacy and Pharmacology, University of Bath, Bath, UK 
Short title: Pregnancy losses in women with diabetes 
Submission to: Diabetic Medicine 
 
Correspondence: 
Dr. Anita McGrogan 
Department of Pharmacy and Pharmacology 
University of Bath 
Bath 
BA2 7AY 
 
Email: a.mcgrogan@bath.ac.uk 
 
Telephone:  +44 (0) 1225 384142 
Fax:  +44 (0) 1225 386114 
 
Word count:  Abstract 249 
   Full text 3690 
 
Funding source: This study was funded by Novo Nordisk. 
 
Conflicts of interest: None of the authors have any conflicts of interest that are 
relevant to the content of this paper. 
2 
 
 
Novelty statement: 
 Proportions of pregnancies resulting in deliveries and losses in women with 
type 2 diabetes were similar to those in women with type 1 diabetes. 
Using primary care records we found higher overall proportions of losses 
than have previously been reported (type 1 33.4%, type 2 35.4%) and 
higher proportions of spontaneous losses (type 1 19.6%, type 2 21.1%) 
than in the general population (13.2%).  
 
 Oral treatment of type 2 diabetes in the three months before pregnancy 
start date or during the first trimester resulted in the highest proportion of 
spontaneous losses (25%). 
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Abstract 
 
Aim: This study aims to investigate pregnancy losses in women with type 1 and 
type 2 diabetes and compare this with the general population.  
 
Methods: Pregnancies ending between 1993 and 2006 in those with type 1 or 
type 2 diabetes were identified on the General Practice Research Database. 
Pregnancy losses were identified from medical records and the cohort described 
by their characteristics and prescribing for diabetes.  
 
Results: Of 2001 pregnancies identified in women with type 1 diabetes, 678 
ended in a pregnancy loss: 19.6% were spontaneous, 9.6% were induced and 
4.3% were losses for unknown reasons. In women with type 2 diabetes there 
were 240 losses in 669 pregnancies: 21.1% were spontaneous, 10.3% induced 
and 4.0% were losses for unknown reasons. The proportion of spontaneous 
losses in women with diabetes was higher than in the general population 
(13.2%). Women with type 1 diabetes treated with human and analogue insulins 
were 60% more likely to have a delivery than a loss (OR=1.6 CI95 1.18-2.18) 
compared with human insulin treatment alone although numbers were small.  
 
Conclusion  
We found that the proportions of spontaneous losses in women with type 1 and 
type 2 diabetes were similar at approximately 20% which is higher than in the 
general population and also higher than previous studies have reported. While 
much emphasis has been placed on pre-conception care for women with type 1 
diabetes, the same is now needed for those with type 2 diabetes, given the 
similarity in outcomes and increasing prevalence of this condition. 
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Introduction 
Women with pre-existing diabetes are known to have higher rates of spontaneous 
pregnancy loss which is thought to be due to poor glycaemic control. Pre-
pregnancy counselling and planning of pregnancies is advised in order to achieve 
optimum control and thus give the greatest likelihood of a successful pregnancy.  
 
Optimum glycaemic control in women with pre-exiting diabetes in preparation for 
and during pregnancy, especially in the organogenesis phase is the ideal. 
Previous work has indicated an increased rate of spontaneous losses and major 
congenital malformations in the offspring of women with type 1 diabetes (1-3) 
but until recently it was thought that the number of women with type 2 diabetes 
during pregnancy was low (4). Given the increasing age of women having 
pregnancies and the reducing age of diagnosis of type 2 diabetes, this is now not 
the case (5, 6). The aim of this study is to compare proportions of losses between 
women with type 1 and type 2 diabetes and the population who do not have 
diabetes. General practice records will be used to obtain data for the entire 
pregnancy rather than just from referral to secondary care. Other patient factors 
that may also be associated with pregnancy loss will be investigated including 
maternal age, BMI, smoking status and treatment of diabetes. 
 
Patients and methods 
 
Data source 
Pregnancies that ended between 1993 and 2006 and that had prescribing for 
diabetes in the year before or during pregnancy were identified on the General 
Practice Research Database (GPRD). The GPRD contains anonymised primary 
health care records, prescriptions, diagnoses, test results and referrals for around 
7% of the UK population that are recorded for the purposes of patient 
management. The database has been shown to be representative of the 
population of the UK in terms of the geographical location of contributing 
practices, age and sex of patients compared with the general population (7). The 
database is supplied by the Medicines and Healthcare products Regulatory Agency 
who provide indicators of data that is considered to be up to a standard suitable 
for research. Approval for this study was obtained from the GPRD Independent 
Scientific Advisory Committee.  
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Study population 
Pregnancy losses were identified by an algorithm (8) that determined whether the 
loss was spontaneous or if it was induced for medical or non-medical reasons. 
Medical diagnoses, test and referral data were used to determine this 
classification. Where the algorithm was not able to classify the reason for the 
termination, extra information was requested in the form of ‘free text’ which 
included referral, hospital letters and notes made by the GP. This was requested 
for one month before and three months after the pregnancy end date. To be 
included in this study, each patient needed to have at least one medical code for 
diagnosis of type 1 or type 2 diabetes before the start of pregnancy and at least 
one prescription for diabetes medication in the year before the start of pregnancy  
or during pregnancy. This ensured that only those with pre-existing diabetes were 
included in the cohort. This excluded women with gestational diabetes and type 2 
diabetes treated by diet alone. 
 
Data collected 
Prescriptions issued for diabetes medication were classified by type of insulin 
(animal, human, analogue) and type of oral treatment (biguanide, sulphonylurea, 
other oral) by three month period. All individuals included had to have at least 
one year of data up to research standard before pregnancy start date and at least 
three months of data after pregnancy end date and to be aged between 11 and 
49 years at the end of their pregnancy. Pregnancy loss was reported by trimester 
and according to treatment regimen. Patient characteristics including age, BMI 
and smoking status at the start of pregnancy were identified. 
 
Classification of diabetes 
Type of pre-existing diabetes was determined using an algorithm based on 
previous work (9) that identified for each patient their age at first diagnosis of 
diabetes, the diagnosis received, the type of treatment received and use of 
glucose monitoring kits. Any individuals where the type of diabetes could not be 
reliably determined were reviewed manually using a medical records browser that 
we have developed in-house. The browser displays all of the individual’s records 
in chronological order and this was also used to verify diabetes diagnoses for a 
random sample of women. 
 
Analysis 
Descriptive statistics were presented for type of diabetes, type of loss and 
prescribing in the three months before or during the first trimester of pregnancy. 
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This period of prescribing was chosen to avoid information bias because, 
especially for pregnancies in women with type 2 diabetes, prescribing is altered 
during the second or third trimester; for pregnancy loss, prescribing in the first 
trimester is the important consideration. Comparisons of proportions of losses 
were made with all pregnancies identified in the GPRD. This included all 
pregnancies with an end date between 1993 and 2006 occurring in females aged 
between 10 and 49 years at pregnancy start date whose GPRD data was of 
research standard; this excluded those already in the cohort of women with pre-
existing diabetes. Patient characteristics at pregnancy start date were presented 
including BMI, age, smoking status, duration of diabetes, receipt of prescriptions 
for folic acid, medications for hypertension or dyslipidaemia, records indicating 
treatment in secondary care and HbA1c records. Confidence intervals for 
proportions were calculated using the score method with continuity correction 
(10). Multiple logistic regression was used to investigate loss; any missing data 
for BMI or smoking status was coded separately. Model fit was assessed using the 
Hosmer-Lemshow statistic, residuals were checked and leverage was determined 
with any outlying points investigated for their influence on the model fit.   
 
Results 
548 women with type 1 diabetes and 197 women with pharmacologically treated 
type 2 diabetes were identified as having had 909 pregnancy losses on the GPRD 
between 1993 and 2006. Characteristics for these women are given in table 1. 
The most striking differences between those with type 1 and type 2 diabetes were 
in age at pregnancy start date and BMI: 39.9% of those with type 1 diabetes 
compared with 79.6% of those with type 2 diabetes were older than 30 years at 
pregnancy start date; 10.3% of those with type 1 and 52.1% of those with type 2 
diabetes had a BMI greater than 30. However, the proportion of non-smokers was 
higher in those with type 2 diabetes (63.8% versus 46.8%) compared with those 
with type 1 diabetes. Similar proportions of spontaneous losses (type 1: 58.59%, 
type 2: 59.58%; difference -0.99% [CI95% -8.23%, 6.26%]), induced 
terminations (type 1: 28.70%, type 2: 29.17%; difference -0.47% [CI95% -7.16, 
6.23]]) and losses where the type was unknown (type 1: 12.71%, type 2: 
11.25%; difference 1.46% [CI95% -3.27, 6.18]) were found between those with 
type 1 and type 2 diabetes.  
 
Table 2 also compares proportions of outcomes for all pregnancies identified in 
the GPRD and those in women with type 1 or type 2 diabetes. The main 
differences were the lower proportion of deliveries (type 1 66.6%; type 2 64.6%; 
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all GPRD 70.4%) and higher proportion of spontaneous losses in those with 
diabetes (type 1 19.6%; type 2 21.1%; all GPRD 13.2%). This was true in both 
trimesters with spontaneous losses in the second trimester twice the proportion 
of those recorded in all pregnancies in the GPRD (type 1 1.5%, type 2 2.1%, all 
GPRD 0.8%). Freetext reclassified 69 of the pregnancy losses in the type 
‘unknown’ category with over half of these found to be induced terminations. This 
contributed to the reduced frequency of unknown losses in women with diabetes 
compared to all losses in the GPRD.  
 
Fig. 1 shows changes in numbers of deliveries and pregnancy losses over time 
where spontaneous losses in women with type 1 diabetes decreased until 2003 
but in recent years, numbers have increased which has coincided with an increase 
in spontaneous losses in women with type 2 diabetes. However the numbers of 
pregnancy losses each year were small and corresponded to changes in total 
numbers of losses in the database. 
 
Table 3 gives further details about patient management for those with diabetes 
during pregnancy. Over half of women with type 1 diabetes had this diagnosed 
between five and nineteen years before their pregnancy start date whereas 
almost all those with type 2 diabetes were diagnosed fewer than nine years 
before pregnancy start date which also reflects the criteria used for determining 
type of diabetes. Those with the longest durations of type 2 diabetes and shortest 
durations of type 1 diabetes were checked to ensure the diagnosis was correct: 
the duration of diabetes may be incorrectly recorded for those who had moved to 
a contributing GP practice after their diabetes was diagnosed. 6.4% of women 
with type 1 diabetes and 11.9% of women with type 2 diabetes had an HbA1c 
measurement recorded in the three months before their pregnancy start date; in 
the first trimester these proportions were higher: 10.2% of women with type 1 
diabetes and 13.3% of women with type 2 diabetes. Of these records, in the 
three months before pregnancy start date 35-42% indicated blood glucose levels 
<53 mmol/mol (<7.0%): proportions were similar irrespective of pregnancy 
outcome. In the first trimester, of those with recorded HbA1c values, 43.2% of 
women with type 1 diabetes and 54.5% for women with type 2 diabetes whose 
pregnancies resulted in a delivery had an HbA1c value <53mmol/mol (<7.0%). 
For pregnancies that resulted in a loss, these proportions were much lower (type 
1: 26.3%, p=0.026; type 2: 25%, p=0.003) although numbers of records were 
small. 
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The GPRD data indicated that in the three months before and during the first 
trimester of pregnancy 183 women received prescriptions for medications for 
hypertension and 84 women received prescriptions for dyslipidaemia. 
 
Utilisation 
Type 1: Differences between type of pregnancy loss and prescribing can be seen 
in table 4. The lowest proportion of deliveries occurred in those only receiving 
prescriptions for analogue insulin (54.6% [CI95% 47.6 – 61.5]) whereas the 
highest proportion of deliveries occurred in those receiving prescriptions for 
human and analogue insulins (76.5% [CI95% 71.2 - 81.2]). Differences in 
proportions of pregnancy losses were also apparent with a greater proportion of 
induced terminations in those using analogue insulin (19.8% [CI95% 14.7 – 26.0]) 
compared with those using human insulin (8.4 [CI95% [6.9 – 10.1]); of these 
induced terminations, 33 (of 41; 80.5%) were for non-medical reasons for those 
using analogue insulin and 68 (of 107; 63.6%) for those using human insulin, 
however caution is required given the low numbers.  
 
The results of the logistic regression model adjusting for age, BMI and smoking 
status are reported in the supplementary appendix. The model provided a good fit 
to the observed data (Hosmer-Lemeshow statistic p=0.69); removing 
observations found to have high leverage did not substantially alter the risk 
estimates presented. The results of the logistic regression indicated a moderately 
increased odds of delivery compared to loss [1.60 (CI95%1.18, 2.18)] in those 
using human and analogue insulin in the three months before or during the first 
trimester of pregnancy compared to human insulin. Age, BMI and smoking status 
also influenced odds of delivery with age over 35 years reducing odds of delivery 
compared to age 30-34 years, BMI ≥ 40 reducing odds of delivery compared to a 
BMI of 20-24 [0.23 (CI95% 0.08-0.73)] and smokers having a reduced odds of 
delivery compared to non-smokers [0.57 (CI95%0.46-0.71)].  
 
Type 2: 
The main differences observed were in the higher proportions of losses in those 
receiving just oral treatment products: of all outcomes in those receiving 
prescriptions for biguanides alone, 27.5% (CI95% 19.3 – 37.3) were spontaneous 
losses; of all outcomes in those receiving prescriptions for other oral products 
(mainly sulphonylureas), 24.6% (CI95% 14.5 – 38.0) were spontaneous losses and 
26.3% (CI95% 15.9 – 39.9) were induced losses. However the numbers in these 
groups were small which limited further interpretation.  
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The results of the logistic regression given in the supplementary appendix were 
adjusted for age, BMI and smoking status. The fit of the model was good 
(Hosmer-Lemeshow statistic p=0.85) and adjusting for observations with high 
leverage did not affect the original estimates found. The model indicated that 
biguanide or other oral treatment alone gave a reduced odds of delivery 
compared to insulin treatment. Those who didn’t receive any treatment in the 
three months before pregnancy or during the first trimester had an increased 
odds of delivery which may indicate milder cases of type 2 diabetes (2.43 
[CI95%1.24, 4.77]). Increasing age contributed to a reduced odds of delivery for 
those aged 40 years and older (0.54 [CI95% 0.31, 0.92]).  
 
Discussion 
 
In this study we have investigated pregnancy losses in women with pre-existing 
type 1 and type 2 diabetes using primary care records. This study has 
demonstrated the value of general practice records in studying this important 
subject. We found a similar proportion of spontaneous losses in those with type 1 
(19.6%) and type 2 diabetes (21.1%) and as expected, this is higher than in the 
general population (13.2%).  The St. Vincent declaration of 1989 aimed to 
improve pregnancy outcomes in women with insulin dependent diabetes to be of 
an equivalent level to outcomes in women who do not have diabetes (11). It is 
clear that while outcomes have improved, this aim has not been met.  
 
While a higher rate of pregnancy loss in women with diabetes was expected, the 
rate of loss found in this work was higher than any other rate previously reported 
(3, 4, 6, 11-14). This can be explained by the study design: the majority of 
previous studies recruited women from their first antenatal appointment or from 
hospitals and found rates of spontaneous loss in those with type 1 diabetes to be 
between 13% and 18.6% (3, 4, 6, 11-14); these studies may have missed losses 
early in pregnancy whereas here, by using primary care records we have included 
all but the very earliest of losses.  
 
There have been few studies of pregnancy outcomes in women with type 2 
diabetes but since the prevalence of type 2 diabetes is increasing in younger 
women this needs to be rectified (15). It is striking that we found the proportions 
of losses were very similar for women with type 1 and type 2 diabetes since type 
2 diabetes was previously thought to be a less serious condition than type 1 
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diabetes, both during and outside of pregnancy (15). It is possible that the rate of 
losses in those with type 2 diabetes has been overestimated by our study since 
we only included women who were being treated pharmacologically and therefore 
only those with a more severe condition. Other studies however suggest that this 
is unlikely: Murphy et al. (6) reported that 26.6% of women with type 2 diabetes 
were managed on diet alone at conception but 90% received fast acting insulin 
analogues during pregnancy; Dunne (16) reported that most women with type 2 
diabetes received treatment during pregnancy. 
 
Cundy et al. (17) indicated that pregnancy losses in women with type 1 diabetes 
were likely to be due to congenital malformations but in type 2 diabetes were 
more likely to be due to asphyxia, stillbirth and chorioamniotis. We found a higher 
proportion of induced terminations for medical reasons (mostly major congenital 
malformations) in women with type 1 diabetes. There was a slightly higher 
proportion of terminations for non-medical reasons in women with type 2 
diabetes which may indicate more unplanned pregnancies. 
 
Risk factors for type 2 diabetes include obesity, increasing age, having a non-
Caucasian background and being of lower socio-economic status (17-19) 
therefore it was unsurprising that the distribution of these factors was different 
between those with type 1 and type 2 diabetes. Murphy et al. (6) and CEMACH 
(19) found similar proportions of women with type 2 diabetes were overweight or 
obese at enrolment (90% and 84% respectively): this corresponded to 87% 
found in our study. We found that increasing age and very high BMI reduced the 
odds of delivery in women with type 1 diabetes. This is in contrast with Temple et 
al. (14) who did not find an increased risk of spontaneous loss with age, weight 
or smoking in women with type 1 diabetes but did report an increase in risk with 
lack of pre-pregnancy care. While pre-pregnancy care has been highlighted by 
many as vital in the management of women with type 1 diabetes, those with type 
2 diabetes may be less likely to receive this (15). Cundy found that women with 
type 2 diabetes presented for antenatal care on average 5 weeks later than those 
with type 1 diabetes but CEMACH reported no differences in antenatal care 
between those with type 1 and type 2 diabetes (19).   
 
We found that only a small proportion of women had an HbA1c measurement 
recorded in their notes in the three months before pregnancy (type 1: 6.4%, type 
2: 11.9%) or during the first trimester (type 1: 10.2%, type 2: 13.0%) but the 
higher proportion of women with type 2 diabetes with these records compared 
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with women with type 1 diabetes is surprising. Of these measurements, less than 
half indicated optimal glycaemic control which has implications for organogenesis 
and pregnancy loss. However, given the small numbers it is difficult to speculate 
whether this represents a wider trend. Numbers of women receiving prescriptions 
for statins and hypertension medication such as ACE inhibitors were low but are 
of concern given that these medications are contraindicated in pregnancy: this 
may indicate unplanned pregnancies. We found very few records indicating that 
women had their diabetes managed in secondary care (type 1: 61; type 2: 39) 
although these figures could be underreported in the database. Fewer than one 
third of women received prescriptions for folic acid during the first trimester of 
pregnancy however since low dose folic acid is available to buy over the counter 
this is unlikely to fully represent all those taking folic acid. 
 
Very few studies have reported on the diabetes treatment received in conjunction 
with pregnancy outcomes. The NICE guidelines recommend the use of rapid-
acting analogue insulins over soluble human insulin for type 1 diabetes and that 
use of glibenclamide and metformin should be assessed individually for each 
patient with type 2 diabetes. Lambert and Holt (20) have recently reviewed the 
evidence on the use of insulin analogues in pregnancy and recommend their use 
although information on foetal outcomes is still needed for some insulins. We 
found an increased odds of delivery in women with type 1 diabetes who used 
human and analogue insulin compared to human insulin alone while use of 
analogue insulin individually reduced the odds of having a delivery. Given that 
analogue insulin and evidence for its use has only become available in the later 
years of this study period, those who received prescriptions only for this may 
have different indications such as poor glycaemic control or hypoglycaemia. The 
small numbers of those receiving prescriptions for analogue insulin is a limitation 
of this study. Given the confounding factors relating to the choice of medication 
prescribed and the limited sample size of this study it is not possible to draw 
conclusions regarding potential benefits or risks of individual treatments 
prescribed for diabetes during pregnancy.  
 
In type 2 diabetes those who did not receive treatment in the three months 
before pregnancy or during the first trimester of pregnancy had an increased 
odds of delivery compared to loss which may indicate a less severe condition. 
Whereas those who received only oral products had higher proportions of losses 
than those receiving insulin. This could indicate a lack of pre-pregnancy care or 
unplanned pregnancies, although the numbers found were small. Both studies (6, 
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17) that reported on outcomes of women with type 2 diabetes indicated that the 
majority used insulin during pregnancy.  
While every effort has been made to correctly classify the type of diabetes 
diagnosed through the identification of GP’s diagnoses, prescribing records, age 
of diagnosis and use of home monitoring equipment, there may be some 
misclassification. For example, where type 2 diabetes has occurred in those who 
are young or where treatment for type 2 diabetes has been solely with insulin. 
We expect that this would only occur very rarely and by using our in-house 
browser to review full medical records this will have minimised any associated 
errors. We have reviewed freetext entries for any outcomes that were reported to 
be terminations for unknown reasons, to identify whether more information 
existed about these outcomes. It was surprising to find women with type 1 
diabetes who did not have prescribing in the three months before or after 
conception. A thorough check of all of these individuals’ records indicated that 
they were diagnosed with type 1 diabetes and that all received prescriptions for 
insulin (mainly human insulin) during the year before pregnancy and also in later 
trimesters for those pregnancies that ended in a delivery. Prescribing records on 
the GPRD are known to be at least 95% complete (21) but there is the potential 
for women with diabetes to have their condition managed in secondary care. 
However, we found that the number of women who had a record for treatment in 
secondary care for diabetes was small. A limitation of this study is the low 
reporting of HbA1c or other measures of glycaemic control that were found in the 
GPRD. It is expected that these measurements are taken but not routinely 
recorded.  
 
In summary, we have found that using primary care records to study pregnancy 
losses in women with pre-existing diabetes led to higher rates of pregnancy 
losses being found than have previously been reported. The proportions of losses 
in women with type 1 (33.4%) and type 2 diabetes (35.4%) were similar with a 
greater proportion of spontaneous losses (type 1 19.6%, type 2 21.1%) occurring 
compared with the general population (13.2%). These findings are very important 
when considering the increasing prevalence of type 2 diabetes in women of child-
bearing age. While there have been improvements in pregnancy outcomes in 
women with diabetes following the St. Vincent declaration, emphasis on the 
evaluation of oral medication, given its widespread use in managing diabetes in 
pregnancy, is now needed. 
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Table 1: Patient characteristics for women with type 1 or type 2 diabetes who 
had a pregnancy loss. Characteristics for all women with pregnancy losses 
recorded in the General Practice Research Database who were aged 10-49 years 
at pregnancy start date, whose pregnancies commenced between 1992 and 2006 
and where data was of a standard suitable for research are also given; those in 
the population of women with pre-existing diabetes were excluded from the ‘All 
GPRD’ group. 
  
  Type 1 Type 2  All GPRD 
    N % N % p N % 
Pregnancy 
losses 
  669   240     
172927   
Age (years) 11-14 1 
 
0 
  
635 0.37 
 
15-19 81 12.1 4 
 
<0.001 24728 14.30 
 
20-24 151 22.6 16 6.7 <0.001 36014 20.83 
 
25-29 166 24.8 29 12.1 <0.001 37730 21.82 
 
30-34 146 21.8 79 32.9 <0.001 37048 21.42 
 
35-39 94 14.1 59 24.6 <0.001 25197 14.57 
 
40-44 27 4 40 16.7 <0.001 10287 5.95 
  45-49 3   13 5.4   1288 0.74 
BMI (kgm-2) <20 34 5.1 4 1.7 
 21571 12.47 
 
20-24 268 40.1 28 11.7 <0.001 64073 37.05 
 
25-29 153 22.9 57 23.8 0.782 25525 14.76 
 
30-34 48 7.2 61 25.4 <0.001 8638 5.00 
 
35-39 21 3.1 39 16.3 <0.001 2896 1.67 
 
≥40 9 
 
25 10.4 <0.001 1325 0.77 
  Unknown 136 20.3 26 10.8 0.001 48899 28.28 
Smoking status Smoker 251 37.5 65 27.1 <0.001 64544 37.32 
 
Non-
smoker 
313 46.8 153 63.8 <0.001 
81803 47.30 
 
Ex-
smoker 
82 12.3 20 8.3 0.099 
15724 9.09 
  Unknown 23 3.4 2 0.8   10856 6.28 
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Table 2: Numbers and proportions of deliveries and pregnancy losses for women 
with type 1 and type 2 diabetes during pregnancy and for all pregnancies 
recorded in the General Practice Research Database (GPRD). All pregnancies 
included in the study were in women who were aged 10-49 years at pregnancy 
start date, whose pregnancies commenced between 1992 and 2006 and where 
data was of a standard suitable for research and excluded those identified in the 
population of women with pre-existing diabetes. 
 
Outcome  Trim Type 1 Type 2 
 
All in GPRD 
    N % (CI 95%) N % (CI 95%) Difference (CI 95%) N % (CI 95%) 
Spontaneous 
loss 
1 362 18.1 (16.4-19.9) 129 19.0 (16.2-22.2) 
 -0.9% (-4.34%, 
2.47%) 
72019 
12.33 (12.25 - 
12.42) 
 
2 30 1.5 (1.0 -2.2) 14 2.1 (1.2 - 3.5) 
 
4886 
0.84 (0.81 - 
0.86) 
Induced loss 1 183 9.1 (7.9 - 10.5) 70 10.3 (8.2 - 12.9) 
 -1.2% (-3.79%, 
1.44%) 
53754 
9.21 (9.14 - 
9.28) 
 
2 9 0.4 (0.2 - 0.9) 0 0 (0 - 0.7) 
 
1124 
0.19 (0.18 - 
0.20) 
Unknown loss 1 82 4.1 (3.3 - 5.1) 25 3.7 (2.5 - 5.5) 
 0.4% (-1.25%, 
2.07%) 
39885 
6.83 (6.77 - 
6.90) 
  2 3 0.1 (0.04 - 0.5) 2 0.3 (0.1 - 1.2)   1259 
0.22 (0.20 - 
0.23) 
Total losses   669 
33.3 (31.2 - 
35.5) 
240 35.4 (31.8 - 39.2) 
 -2.0% (-6.12%, 
2.19%) 
172927 
29.63 (29.51 - 
29.74) 
Total deliveries   1332 
66.6 (64.4 - 
68.6) 
438 64.6 (60.9 - 68.2) 
 2.2% (-2.19%, 
6.12%) 
410761 
70.37 (70.26 - 
70.49) 
Total 
outcomes 
  2001   678     583688   
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(a) 
 
(b) 
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(c) 
 
Figure 1: Numbers of deliveries and pregnancy losses including type of loss by 
year of start date for (a) type 1 diabetes (DM1), (b) type 2 (DM2) diabetes and 
(c) for all of the pregnancy losses on the General Practice Research Database 
(GPRD). (c) included all women who were aged 10-49 years at pregnancy start 
date, whose pregnancies commenced between 1992 and 2006 and where data 
was of a standard suitable for research and excluded those identified in the 
population of women with pre-existing diabetes.. 
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Table 3: Details about duration of diabetes, treatment received in secondary 
care, HbA1c measurements, folic acid and medications for hypertension and 
dyslipidaemia recorded in the General Practice Research Database. p-values 
indicate the comparison of characteristics between women with type 1 and type 2 
diabetes for pregnancies resulting in a delivery (p delivery) or a loss (p loss). 
 
Type 1 Type 2  
   Delivery Loss Delivery Loss p delivery p loss 
Duration of diabetes (years) 
     <2 107 (8.03) 52 (7.77) 132 (30.14) 85 (35.42) <0.001 <0.001 
2-4 183 (13.74) 91 (13.6) 155 (35.39) 70 (29.17) <0.001 <0.001 
5-9 261 (19.59) 131 (19.58) 112 (25.57) 51 (21.25) 0.08 0.58 
10-14 241 (18.09) 159 (23.77) 34 (7.76) 30 (12.5) <0.001 <0.001 
15-19 241 (18.09) 110 (16.44) 5 (1.14) 2 (0.83) <0.001 <0.001 
20-24 188 (14.11) 75 (11.21) 0 2 (0.83) <0.001 <0.001 
25-29 79 (5.93) 34 (5.08) 0 0 <0.001 <0.001 
30-34 27 (2.03) 17 (2.54) 0 0 0.009 0.02 
35-39 5 (0.38) 0 0 0 0.6   
Treatment in secondary care recorded 
    3 months before LMP 9 (0.68) 4 (0.6) 5 (1.14) 2 (0.83) 0.42 >0.99 
During pregnancy 37 (2.78) 8 (1.2) 19 (4.34) 9 (3.75) 0.11 0.03 
Both 3 (0.23) 0 2 (0.46) 2 (0.83) 0.43 0.03 
Folic acid prescriptions issued 
   Year before LMP 
      Low dose (350-500mcg) 81 (6.08) 35 (5.23) 32 (7.31) 33 (13.75) 0.36 <0.001 
High dose (5mg) 105 (7.88) 29 (4.33) 19 (4.34) 9 (3.75) 0.01 0.7 
Trimester 1 
    
  
Low dose (350-500mcg) 175 (13.14) 55 (8.22) 92 (21) 21 (8.75) <0.001 0.8 
High dose (5mg) 175 (13.14) 62 (9.27) 65 (14.84) 15 (6.25) 0.37 0.15 
HbA1c measurements recorded 
    3 months before LMP 
      < 53mmol/mol (<7%) 30 (2.25) 17 (2.54) 22 (5.02) 11 (4.58) 0.005 0.12 
53-86 mmol/mol (7-
10%) 36 (2.7) 19 (2.84) 23 (5.25) 11 (4.58) 
0.01 0.19 
> 86 mmol/mol (>10%) 14 (1.05) 12 (1.79) 7 (1.6) 7 (2.92) 0.36 0.3 
Trimester 1 
    
  
< 53mmol/mol (<7%) 64 (4.8) 15 (2.24) 36 (8.22) 6 (2.5) 0.007 0.59 
53-86 mmol/mol (7-
10%) 63 (4.73) 22 (3.29) 24 (5.48) 10 (4.17) 
0.53 0.53 
> 86 mmol/mol (>10%) 21 (1.58) 20 (2.99) 6 (1.37) 8 (3.33) 0.76 0.79 
Trimester 2 
    
  
< 53mmol/mol (<7%) 101 (7.58) 3 (7.14) 38 (8.68) 2 (0.89) 0.46 0.85 
53-86 mmol/mol (7-
10%) 33 (2.48) 3 (7.14) 19 (4.34) 1 (0.45) 
<0.001 >0.99 
> 86 mmol/mol (>10%) 10 (0.75) 2 (4.76) 2 (0.46) 1 (0.45) 0.8 >0.99 
Trimester 3 
    
  
< 53mmol/mol (<7%) 96 (7.25)  -  37 (8)  -  0.37  -  
53-86 mmol/mol (7-
10%) 24 (1.81)  -  14 (3.23)  -  0.08  -  
> 86 mmol/mol (>10%) 5 (0.38)  -  1 (0.23)  -  0.99  -  
Other medications prescribed in pregnancy  
    ACE inhibitor 
      3 months before LMP 22 (1.65) 12 (1.79) 6 (1.39) 5 (2.23) 0.68 0.78 
Trimester 1 2 (0.15) 2 (0.3) 6 (1.39) 3 (1.34) 0.007 0.24 
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Both periods 11 (0.83) 12 (1.79) 23 (5.31) 10 (4.46) <0.001 0.04 
Angiotensin II receptor blocker 
   
 
 3 months before LMP 1 (0.08) 1 (0.15) 3 (0.69) 2 (0.89) 0.1 0.34 
Trimester 1 0 1 (0.15) 1 (0.23) 0 0.87 >0.99 
Both periods 3 (0.23) 3 (0.45) 1 (0.23) 4 (1.79) 0.99 0.17 
Beta blockers 
    
  
3 months before LMP 2 (0.15) 1 (0.15) 5 (1.15) 1 (0.45) 0.02 0.92 
Trimester 1 3 (0.23) 3 (0.45) 4 (0.92) 3 (1.34) 0.14 0.38 
Both periods 11 (0.83) 4 (0.6) 11 (2.54) 7 (3.13) 0.006 0.02 
Calcium channel blockers 
    
  
3 months before LMP 4 (0.3) 2 (0.3) 3 (0.69) 0 (0) 0.48 0.79 
Trimester 1 1 (0.08) 1 (0.15) 3 (0.69) 1 (0.45) 0.1 0.92 
Both periods 9 (0.68) 3 (0.45) 9 (2.08) 6 (2.68) 0.04 0.03 
Thiazide 
    
  
3 months before LMP 8 (0.6) 1 (0.15) 5 (1.15) 5 (2.23) 0.4 0.01 
Trimester 1 0 1 (0.15) 2 (0.46) 0 0.31 >0.99 
Both periods 2 (0.15) 1 (0.15) 8 (1.85) 5 (2.23) <0.001 0.01 
Statin 
    
  
3 months before LMP 4 (0.3) 6 (0.9) 7 (1.62) 5 (2.23) 0.01 0.27 
Trimester 1 2 (0.15) 2 (0.3) 5 (1.15) 3 (1.34) 0.024 0.24 
Both periods 12 (0.9) 9 (1.35) 12 (2.77) 11 (4.91) 0.004 0.003 
Other lipid regulating medications 
   
  
3 months before LMP 0 0 0 0  
 Trimester 1 0 0 0 0  
 Both periods 1 (0.08) 2 (0.3) 5 (1.15) 1 (0.45) 0.009 >0.99 
 
Note: LMP: last menstrual period
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Table 4: Outcomes and prescribing in the three months before pregnancy and 
during the first trimester for women with type 1 and type 2 diabetes. Numbers 
(N) and proportions (%) with 95% confidence intervals are given for each 
outcome. 
 
Outcome Spontaneous loss Induced loss 
Loss for unknown 
reason 
Delivery 
  N % (CI95%) N % (CI95%) N % (CI95%) N % (CI95%) 
Type 1         
Human  258 20.2 (18.0 - 22.5) 107 8.4 (6.9 - 10.1) 66 5.2 (4.0 - 6.6) 849 66.3 (63.7 - 68.9) 
Analogue 48 23.2 (17.7 - 29.7) 41 19.8 (14.7 - 26.0) 5 2.4 (0.9 - 5.9) 113 54.6 (47.6 - 61.5) 
Animal 17 16.8 (10.4 - 25.9) 14 13.9 (8.1 - 22.5) 3 3.0 (0.8 - 9.1) 67 66.3 (56.2 - 75.3) 
Human and 
analogue 
40 13.6 (10.0 - 18.2) 22 7.5 (4.9 - 11.3) 7 2.4 (1.0 - 5.1) 225 
76.5 (71.2 - 81.2) 
Other 15 31.3 (19.1 - 46.4) 1 2.1 (0.1 - 12.5) 1 
2.1 (0.1 - 
12.5) 
31 
64.6 (49.4 - 77.5) 
Nothing 14 19.7 (11.6 - 31.2) 8 11.3 (5.3 - 21.5) 2 
2.8 (0.5 - 
10.7) 
47 
66.2 (53.9 - 76.7) 
Type 2        
 Insulin 50 20.8 (16.0 - 26.6) 19 7.9 (5.0 - 12.3) 9 3.8 (1.8 - 7.2) 162 67.5 (61.1 - 73.3) 
Biguanide 28 27.5 (19.3 - 37.3) 15 14.7 (8.7 - 23.4) 7 
6.8 (3.0 - 
14.1) 
52 
51.0 (41.0 - 60.9) 
Oral 
treatment1 
14 24.6 (14.5 - 38.0) 15 26.3 (15.9 - 39.9) 6 
10.5 (4.4 - 
22.2) 
22 
38.6 (26.3 - 52.4) 
Biguanide 
and oral 
treatment1 
11 21.2 (11.5 - 35.1) 7 13.5 (6.0 - 26.4) 2 
3.8 (0.7 - 
14.3) 
32 
61.5 (47.0 - 74.4) 
Insulin and 
biguanide 
18 23.1 (14.6 - 34.3) 3 3.8 (1.0 - 11.6) 2 2.6 (0.4 - 9.8) 55 
70.5 (59.0 - 80.0) 
Insulin and 
oral 
treatment1 
6 22.2 (9.4 - 42.7) 2 7.4 (1.3 - 25.8) 0 0 (0 - 15.5) 19 
70.4 (49.7 - 85.5) 
Insulin, 
biguanide 
and oral 
treatment1 
9 20.9 (10.6 - 36.5) 5 11.6 (4.4 - 25.9) 0 0 (0 - 10.2) 29 
67.4 (51.3 - 80.5) 
Nothing 7 8.9 (3.9 - 18.0) 4 5.1 (1.6 - 13.2) 1 
1.3 (0.07 - 
7.8) 
67 
84.8 (74.6 - 91.6) 
1 Oral treatment included any other anti-diabetic treatment that is not a biguanide or insulin 
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Supplementary appendix: Odd ratios (OR) and 95% confidence intervals 
(CI95%) for delivery compared to pregnancy loss in type 1 and type 2 diabetes 
with prescribing in the three months before and first trimester of pregnancy. 
Model estimates were adjusted for age, BMI and smoking status. 
 
 
 
Type 1 Type 2 
Age OR (CI95%) OR (CI95%) 
15-19 0.26 (0.17, 0.39) 0.30 (0.06, 1.47) 
20-24 0.54 (0.40, 0.72) 0.58 (0.27, 1.26) 
25-29 0.90 (0.69, 1.17) 1.42 (0.84, 2.40) 
30-34 Reference Reference 
35-39 0.58 (0.42, 0.80) 1.02 (0.67, 1.56) 
40-44 0.39 (0.22, 0.69) 0.54 (0.31, 0.92) 
45-49 0.36 (0.07, 1.90) 0.30 (0.11, 0.83) 
BMI 
  <20 0.89 (0.55, 1.43) 0.20 (0.04, 0.97) 
20-24 Reference Reference 
25-29 1.11 (0.87, 1.42) 0.69 (0.39, 1.25) 
30-34 1.17 (0.80, 1.71) 0.58 (0.32, 1.04) 
35-39 0.67 (0.37, 1.21) 0.65 (0.34, 1.24) 
≥40 0.23 (0.08, 0.73) 0.68 (0.33, 1.38) 
Unknown 0.86 (0.65, 1.13) 0.85 (0.42, 1.71) 
Smoking status 
  Non-smoker Reference Reference 
Smoker 0.57 (0.46, 0.71) 0.80 (0.54, 1.20) 
Ex-smoker 0.87 (0.64, 1.18) 1.88 (1.04, 3.37) 
Unknown 1.05 (0.60, 1.85) 0.84 (0.12, 5.80) 
Treatment  
  Human  Reference 
 Analogue 0.64 (0.47, 0.88) 
 Animal 0.83 (0.53, 1.30) 
 Human and analogue 1.60 (1.18, 2.18) 
 Other combination 0.97 (0.52, 1.81) 
 No treatment 
 
2.43 (1.24, 4.77) 
Insulin alone Reference 
Biguanide alone 0.51 (0.31, 0.84) 
Oral alone 
 
0.33 (0.18, 0.63) 
Biguanide and oral 
 
0.80 (0.42, 1.53) 
Insulin and biguanide 1.02 (0.57, 1.83) 
Insulin and oral 
 
0.92 (0.37, 2.24) 
Insulin, oral, biguanide 1.19 (0.58, 2.45) 
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